Samarium for osteoblastic bone metastases and osteosarcoma (Q28253337)

Europe PubMed Central

title

Samarium for osteoblastic bone metastases and osteosarcoma (English)

2 references

26 March 2017

25 May 2017

0 references

Pete Anderson

1

2 references

26 March 2017

25 May 2017

language of work or name

English

0 references

publication date

August 2006

0 references

21 July 2006

2 references

26 March 2017

Expert Opinion on Pharmacotherapy

25 May 2017

published in

2 references

26 March 2017

25 May 2017

volume

7

2 references

26 March 2017

25 May 2017

issue

11

2 references

26 March 2017

25 May 2017

page(s)

1475-86

0 references

1475-1486

2 references

26 March 2017

Radioisotopes for the palliation of metastatic bone cancer: a systematic review

25 May 2017

cites work

2 references

https://api.crossref.org/works/10.1517/14656566.7.11.1475

21 April 2017

https://api.crossref.org/works/10.1517/14656566.7.11.1475

Targeting of therapeutic agents to bone to treat metastatic cancer

27 May 2017

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

Pain control by ionizing radiation of bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

Management of bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

Bone metastases: approaches to management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

Palliative radiotherapy in the treatment of skeletal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

Presenting symptoms in patients referred to a multidisciplinary clinic for bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

Prostate cancer metastases to bone: pathophysiology, pain management, and the promise of targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

Bisphosphonates and radiation therapy for palliation of metastatic bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

Relative roles of bone scintigraphy and positron emission tomography in assessing the treatment response of bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

186Re-HEDP for metastatic bone pain in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

Systemic radionuclide therapy in pain palliation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

Radioisotopes in the treatment of bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

Strontium and samarium therapy for bone metastases from prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

Use of radionuclides for the palliation of bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

Low toxicity and efficacy of (153)samarium-EDTMP and melphalan as a conditioning regimen for secondary acute myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

Outcome of myeloablative allogeneic stem cell transplantation in multiple myeloma with a 153Sm-EDTMP-based preparative regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

Bisphosphonates in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

Future directions in the treatment and prevention of bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

Samarium-153 EDTMP therapy of disseminated skeletal metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

A method for measurement of the uptake patterns of two beta-emitting radionuclides in the same tissue section with a digital silicon detector: application to a study of 89SrCl2 and 153Sm-EDTMP in a dog with spontaneous osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

[153Sm]EDTMP: a potential therapy for bone cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

Analysis of urine samples from metastatic bone cancer patients administered 153Sm-EDTMP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

Dosimetry and toxicity of Quadramet for bone marrow ablation in multiple myeloma and other haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

Samarium-153-labelled EDTMP for bone metastases from cancer of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

Dose response relationship and multiple dose efficacy and toxicity of samarium-153-EDTMP in metastatic cancer to bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

Efficacy and safety of repeated samarium-153 lexidronam treatment in a patient with prostate cancer and metastatic bone pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

A comparative study of samarium-153-ethylenediaminetetramethylene phosphonic acid with pamidronate disodium in the treatment of patients with painful metastatic bone cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

Lack of effect of a bisphosphonate (pamidronate disodium) infusion on subsequent skeletal uptake of Sm-153 EDTMP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

Patient dosimetry in radionuclide therapy: the whys and the wherefores

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.7.11.1475

10.1517/14656566.7.11.1475

21 January 2018

Identifiers

DOI

2 references

26 March 2017

release_pyc3oainfjhormi6zs534qslwe

25 May 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/pyc3oainfjhormi6zs534qslwe